<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Exact Sciences Cancer Diagnostics Portfolio - Pricing Guide</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #e0f7fa 0%, #b2ebf2 100%);
            padding: 40px 20px;
            line-height: 1.6;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0, 0, 0, 0.1);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #26c6da 0%, #00acc1 100%);
            color: white;
            padding: 40px;
            text-align: center;
        }
        
        .header h1 {
            font-size: 2.5em;
            margin-bottom: 10px;
            font-weight: 600;
        }
        
        .header .subtitle {
            font-size: 1.2em;
            opacity: 0.95;
        }
        
        .stats {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            padding: 30px 40px;
            background: #e0f2f1;
        }
        
        .stat-box {
            background: white;
            padding: 20px;
            border-radius: 12px;
            text-align: center;
            border-left: 4px solid #26c6da;
        }
        
        .stat-box .number {
            font-size: 2em;
            font-weight: bold;
            color: #00838f;
            margin-bottom: 5px;
        }
        
        .stat-box .label {
            color: #546e7a;
            font-size: 0.95em;
        }
        
        .content {
            padding: 40px;
        }
        
        .section {
            margin-bottom: 40px;
        }
        
        .section-title {
            font-size: 1.8em;
            color: #00838f;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 3px solid #b2ebf2;
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
            margin-bottom: 30px;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.08);
            border-radius: 8px;
            overflow: hidden;
        }
        
        thead {
            background: linear-gradient(135deg, #80deea 0%, #4dd0e1 100%);
            color: #004d40;
        }
        
        th {
            padding: 18px 15px;
            text-align: left;
            font-weight: 600;
            font-size: 1.05em;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        tbody tr:nth-child(odd) {
            background: #e0f7fa;
        }
        
        tbody tr:nth-child(even) {
            background: white;
        }
        
        tbody tr:hover {
            background: #b2ebf2;
            transition: background 0.3s ease;
        }
        
        td {
            padding: 16px 15px;
            border-bottom: 1px solid #e0f2f1;
        }
        
        .product-name {
            font-weight: 600;
            color: #00695c;
            font-size: 1.05em;
        }
        
        .price {
            font-weight: bold;
            color: #00838f;
            font-size: 1.1em;
        }
        
        .highlight {
            background: #fff9c4;
            padding: 2px 8px;
            border-radius: 4px;
        }
        
        .tag {
            display: inline-block;
            background: #26c6da;
            color: white;
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 0.85em;
            margin: 2px;
        }
        
        .tag.new {
            background: #66bb6a;
        }
        
        .tag.flagship {
            background: #ffa726;
        }
        
        .note {
            background: #e0f2f1;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
            border-left: 4px solid #26c6da;
        }
        
        .note strong {
            color: #00695c;
        }
        
        .footer {
            background: #f5f5f5;
            padding: 30px 40px;
            text-align: center;
            color: #546e7a;
            border-top: 3px solid #b2ebf2;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>Exact Sciences Cancer Diagnostics Portfolio</h1>
            <p class="subtitle">Complete Pricing Guide 2025</p>
        </div>
        
        <div class="stats">
            <div class="stat-box">
                <div class="number">$2.76B</div>
                <div class="label">2024 Revenue</div>
            </div>
            <div class="stat-box">
                <div class="number">16%</div>
                <div class="label">Medicare Reimbursement Increase</div>
            </div>
            <div class="stat-box">
                <div class="number">86-98%</div>
                <div class="label">Patients Pay $0</div>
            </div>
            <div class="stat-box">
                <div class="number">20M+</div>
                <div class="label">Cologuard Tests Completed</div>
            </div>
        </div>
        
        <div class="content">
            <!-- Screening & Early Detection -->
            <div class="section">
                <h2 class="section-title">üî¨ Screening & Early Detection Products</h2>
                <table>
                    <thead>
                        <tr>
                            <th>Product</th>
                            <th>Description</th>
                            <th>Medicare Reimbursement</th>
                            <th>Self-Pay Price</th>
                            <th>Patient Cost</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td class="product-name">Cologuard <span class="tag flagship">Flagship</span></td>
                            <td>Multi-target stool DNA test for colorectal cancer and precancerous polyps. 20M+ tests completed since 2014. Coverage every 3 years, ages 45-85.</td>
                            <td class="price">$508</td>
                            <td>Not disclosed</td>
                            <td><strong>96% pay $0</strong><br>Zero cost-sharing Medicare Part B</td>
                        </tr>
                        <tr>
                            <td class="product-name">Cologuard Plus <span class="tag new">New 2025</span></td>
                            <td>Next-generation version: 95% cancer detection (vs 92%), 94% specificity (vs 87%). <strong>40% reduction in false positives.</strong> FDA approved Oct 2024. Launched March 31, 2025.</td>
                            <td class="price">$592 <span class="highlight">+16% vs original</span></td>
                            <td class="price">$790</td>
                            <td><strong>Medicare: $0</strong><br>Most insured: $0<br>35-40% of volumes expected to transition in 2025</td>
                        </tr>
                        <tr>
                            <td class="product-name">Cancerguard <span class="tag new">Sept 2025</span></td>
                            <td>Blood-based multi-cancer early detection test. Detects 19+ cancer types with 68% sensitivity for deadliest cancers and 97.4% specificity. Ages 50-84.</td>
                            <td>No coverage yet<br>(negotiations in progress)</td>
                            <td class="price">$689</td>
                            <td><strong>Self-pay: $689</strong><br>Can use FSA/HSA<br>Imaging Reimbursement Program: <strong>up to $6,000</strong> for follow-up imaging</td>
                        </tr>
                        <tr>
                            <td class="product-name">Cancerguard EX <span class="tag new">H2 2025</span></td>
                            <td>Enhanced multi-cancer detection test launching second half 2025.</td>
                            <td colspan="3" style="text-align: center; font-style: italic;">Pricing not yet disclosed</td>
                        </tr>
                        <tr>
                            <td class="product-name">Riskguard <span class="tag new">Feb 2024</span></td>
                            <td>Hereditary cancer risk assessment analyzing 59 genes across 11 cancer types. Blood, saliva, or buccal swab samples.</td>
                            <td><strong>Covered</strong><br>(rate not disclosed)</td>
                            <td>Not disclosed</td>
                            <td><strong>Medicare: $0</strong> when criteria met<br>Covered by Aetna, Anthem, Cigna, Humana, UnitedHealthcare</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            
            <!-- Precision Oncology -->
            <div class="section">
                <h2 class="section-title">üéØ Precision Oncology & Treatment Guidance</h2>
                <table>
                    <thead>
                        <tr>
                            <th>Product</th>
                            <th>Description</th>
                            <th>Medicare Reimbursement</th>
                            <th>Estimated Price</th>
                            <th>Patient Cost</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td class="product-name">Oncotype DX Breast <span class="tag flagship">Gold Standard</span></td>
                            <td>21-gene assay for HR+/HER2- early-stage invasive breast cancer. Predicts 10-year recurrence risk and chemotherapy benefit. 1M+ patients tested worldwide over 20 years.</td>
                            <td class="price">~$3,416 <br><span style="font-size: 0.9em;">(CPT 81519)</span></td>
                            <td class="price">$3,454 <br><span style="font-size: 0.9em;">(GSA Schedule)</span></td>
                            <td><strong>86% pay $0</strong><br>91% pay <$100<br>Medicare fee-for-service: $0 when criteria met</td>
                        </tr>
                        <tr>
                            <td class="product-name">Oncotype DX DCIS</td>
                            <td>12-gene expression profiling for ductal carcinoma in situ (non-invasive breast cancer).</td>
                            <td class="price">~$3,400</td>
                            <td>~$3,400</td>
                            <td>Similar to Breast test</td>
                        </tr>
                        <tr>
                            <td class="product-name">Oncotype DX Colon</td>
                            <td>Recurrence score test for Stage II colon cancer to determine adjuvant chemotherapy need.</td>
                            <td>Covered</td>
                            <td>~$3,400</td>
                            <td>Similar coverage profile</td>
                        </tr>
                        <tr>
                            <td class="product-name">OncoExTra <span class="tag new">Feb 2023</span></td>
                            <td>Comprehensive genomic profiling across ~20,000 genes and 169 introns. NGS for advanced, metastatic, refractory, relapsed, or recurrent solid tumors. Identifies targetable mutations and clinical trial matches.</td>
                            <td>Covered for NGS component</td>
                            <td>Not disclosed<br><span style="font-size: 0.9em;">(Est. ~$3,500 based on comparables)</span></td>
                            <td><strong>98% pay $0</strong> for NGS component (2024 data)<br>IHC add-ons may have cost-sharing</td>
                        </tr>
                        <tr>
                            <td class="product-name">Oncodetect <span class="tag new">April 2025</span></td>
                            <td>Tumor-informed molecular residual disease (MRD) test tracking up to 200 ctDNA variants. Detects residual cancer after treatment. Serial use over 5 years for Stage II, III, resectable Stage IV CRC.</td>
                            <td><strong>Medicare coverage approved July 9, 2025</strong><br>Rate not disclosed</td>
                            <td class="price">~$3,000 <br><span style="font-size: 0.85em;">(analyst estimate)</span></td>
                            <td><strong>Medicare fee-for-service: $0</strong><br>Commercial coverage expanding<br>Addressable: 150K+ new CRC cases annually</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            
            <!-- PreventionGenetics -->
            <div class="section">
                <h2 class="section-title">üß¨ PreventionGenetics Comprehensive Genetic Testing</h2>
                <table>
                    <thead>
                        <tr>
                            <th>Test Category</th>
                            <th>Details</th>
                            <th>Standard Price</th>
                            <th>Additional Info</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td class="product-name">Hereditary Cancer Panels</td>
                            <td>55 genes across 11+ cancer types: breast, ovarian, uterine, prostate, colorectal, pancreatic, gastric, renal, lung, endocrine, skin</td>
                            <td class="price">$540-$590</td>
                            <td>Medicare: covered with $0 cost when criteria met<br>Commercial insurance widely covered</td>
                        </tr>
                        <tr>
                            <td class="product-name">PGxome Whole Exome Sequencing</td>
                            <td>Comprehensive whole exome sequencing test</td>
                            <td class="price">Standard $990; Rapid $2,290</td>
                            <td>CNV analysis included<br>Free reflex testing to remaining genes<br>Rapid: 14-day expedited turnaround</td>
                        </tr>
                        <tr>
                            <td class="product-name">Standard Test Menu</td>
                            <td>5,000+ genetic tests covering nearly all clinically relevant genes. CLIA-certified, CAP-accredited lab with 25+ PhD geneticists.</td>
                            <td class="price">$990 or less (most tests)</td>
                            <td><strong>Turnaround:</strong> 3 weeks standard, 2 weeks STAT<br><strong>STAT fee:</strong> +25%<br>Custom panels: variable pricing</td>
                        </tr>
                        <tr>
                            <td colspan="4" style="background: #e0f7fa; padding: 15px;">
                                <strong>Sponsored No-Cost Testing Programs:</strong>
                                <ul style="margin-left: 20px; margin-top: 10px;">
                                    <li>Movement disorders panels (938 genes) - Mirum Pharmaceuticals</li>
                                    <li>TTR amyloidosis - AstraZeneca/Ionis</li>
                                    <li>Acute hepatic porphyria - Alnylam</li>
                                    <li>Auditory neuropathy - Regeneron's Amplify program</li>
                                </ul>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            
            <!-- Financial Assistance -->
            <div class="section">
                <h2 class="section-title">üí∞ Patient Financial Assistance Program</h2>
                <div class="note">
                    <strong>Income Eligibility: Up to 400% Federal Poverty Level</strong> - More generous than most programs (200-300% FPL)
                </div>
                
                <table>
                    <thead>
                        <tr>
                            <th>Household Size</th>
                            <th>2025 Income Threshold (400% FPL)</th>
                            <th>Benefit</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>1 person</td>
                            <td class="price">$62,600</td>
                            <td rowspan="5" style="vertical-align: middle;"><strong>Potentially $0 out-of-pocket costs</strong> across all Exact Sciences products<br><br>Automatic qualification if enrolled in: Medicaid, SNAP, SSI, Home Energy Assistance, or similar programs</td>
                        </tr>
                        <tr>
                            <td>2 people</td>
                            <td class="price">$84,600</td>
                        </tr>
                        <tr>
                            <td>3 people</td>
                            <td class="price">$106,600</td>
                        </tr>
                        <tr>
                            <td>4 people</td>
                            <td class="price">$128,600</td>
                        </tr>
                        <tr>
                            <td>Additional person</td>
                            <td class="price">+$22,000 each</td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="note">
                    <strong>Application Methods:</strong>
                    <ul style="margin-left: 20px; margin-top: 10px;">
                        <li><strong>Online:</strong> Complete Patient Assistance Estimator at exactsciences.com</li>
                        <li><strong>Phone:</strong> 866-267-2322 (Oncotype) or 844-870-8870 (Cologuard)</li>
                        <li><strong>Email:</strong> help@exactsciences.com</li>
                        <li><strong>Fax:</strong> 844-870-8875</li>
                        <li><strong>Mail:</strong> ES Labs, Madison, Wisconsin</li>
                    </ul>
                    <p style="margin-top: 15px;"><strong>Required Documentation:</strong> Income verification or proof of government program enrollment. Forms available in English and Spanish.</p>
                </div>
            </div>
            
            <!-- Key Highlights -->
            <div class="section">
                <h2 class="section-title">‚ú® Key Highlights</h2>
                <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(300px, 1fr)); gap: 20px;">
                    <div class="note">
                        <strong>üéØ Market Leadership</strong><br>
                        20 years as gold standard for breast cancer testing (Oncotype DX)<br>
                        18M+ Cologuard tests completed since 2014
                    </div>
                    <div class="note">
                        <strong>üìà 2025 Revenue Guidance</strong><br>
                        $3.13-3.17 billion (continued double-digit growth)<br>
                        15% CAGR target through 2027
                    </div>
                    <div class="note">
                        <strong>üåü Product Innovations</strong><br>
                        3 major launches in 2025: Cologuard Plus, Oncodetect, Cancerguard<br>
                        40% reduction in false positives with Cologuard Plus
                    </div>
                    <div class="note">
                        <strong>üè• Provider Network</strong><br>
                        300,000+ healthcare provider customers<br>
                        200+ large U.S. health systems
                    </div>
                </div>
            </div>
        </div>
        
        <div class="footer">
            <p style="margin-top: 15px; font-size: 0.9em; font-style: italic;">
                All pricing and coverage information accurate as of 2025.
            </p>
        </div>
    </div>
</body>
</html>